SCHEMBL23926351

SCHEMBL23926351

Cc1ccc(O)c(-c2nc(-c3ccccc3O)n3c2CCCC3)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.41
ALDH1A1 P00352 6/20 0.41
HPGD P15428 5/20 0.41
HSD17B10 Q99714 5/20 0.41
TDP1 Q9NUW8 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
USP2 O75604 2/20 0.41
TSHR P16473 2/20 0.41
LMNA P02545 1/20 0.41
MAPK1 P28482 1/20 0.41
MAPT P10636 7/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
GAA P10253 1/20 0.36
RORC P51449 3/20 0.34
TP53 P04637 2/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
HCRTR1 O43613 1/20 0.33
ALOX15 P16050 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30118953 1.00 KDM4E (0.41) KDM4EALDH1A1HPGDHSD17B10TDP1
SCHEMBL23926379 0.96 KDM4E (0.39) KDM4EALDH1A1HPGDHSD17B10TDP1
SCHEMBL30118895 0.96 KDM4E (0.39) KDM4EALDH1A1HPGDHSD17B10TDP1
SCHEMBL30118934 0.87 RORC (0.37) KDM4EALDH1A1HPGDHSD17B10TDP1
SCHEMBL23926372 0.87 RORC (0.37) KDM4EALDH1A1HPGDHSD17B10TDP1
SCHEMBL23926361 0.87 ALDH1A1 (0.37) KDM4EALDH1A1HPGDHSD17B10TDP1
SCHEMBL30118892 0.87 ALDH1A1 (0.37) KDM4EALDH1A1HPGDHSD17B10TDP1
SCHEMBL23926383 0.86 HPGD (0.41) KDM4EALDH1A1HPGDHSD17B10TDP1
SCHEMBL23926341 0.85 RORC (0.38) KDM4EMAPTRORCTP53
SCHEMBL30118929 0.85 RORC (0.38) KDM4EMAPTRORCTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4168408-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES Alterity Therapeutics Limited (AU) 2023-04-26 EP disclosed
CN-115667256-A Compounds for treating diseases and methods of treating diseases 艾特里提治疗有限公司 2023-01-31 CN disclosed
WO-2021253091-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES Alterity Therapeutics Limited (AU) 2021-12-23 WO disclosed
WO-2021253091-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES Alterity Therapeutics Limited (AU) 2021-12-23 WO disclosed
US-11155547-B1 Compounds for and methods of treating diseases Alterity Therapeutics Limited (AU) 2021-10-26 US disclosed
US-11155547-B1 Compounds for and methods of treating diseases Alterity Therapeutics Limited (AU) 2021-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11155547-B1 Compounds for and methods of treating diseases HTT, SNCA, PARK7 KDM4E 1820/4885ALDH1A1 2721/4885HPGD 691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.